Опухоли женской репродуктивной системы

Расширенный поиск

СТАНДАРТЫ АДЪЮВАНТНОЙ ЭНДОКРИНОТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (по материалам 10-й Международной конференции в Сан-Галлене, Швейцария, 2007)

Полный текст:



Об авторах

В. Ф. Семиглазов
ФГУ НИИ онкологии им. проф. Н.Н. Петрова Росмедтехнологий, Санкт-Петербург

В. В. Семиглазов
СПбГМУ им. акад. И.П. Павлова

Список литературы

1. Goldhirsch A., Wood W., Gelber R.D. et al. Progress and promise: highlights o the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133—1134.

2. Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418—8423.

3. Colleoni M., Rotrnensz N., Peruzzotti G. et al. Prognostic role of the extent of peritumoral vascular invasion in-operable breast cancer. Ann Oncol 2007;25 (Supple 18).)

4. Bogaerts J., Cardoso F., Buyse M. et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006;3:540—551.

5. Sparano J.A. TAILOR: trial assigning individualized options for treatment. Clin Breast Cancer 2006;7:347—350.

6. Jimenez-Gordo A.M., De Las Heras B., Zamora P. et al.: Failure of Goserelin ovarian ablation in premenopausal women with breast can- cer: two case reports. Gynecol Oncol 2000;76:126—127.

7. Mauriac L., Keshaviah A., Debled M. et al. Predictors of early relapse in post- menopausal women with hormone recep- tor-positive breast cancer in the BIG 1- 98 trial. Ann Oncol 2007;14:320—327.

8. Barroso G., Menocal G., Felix H. et al. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hor- mone in controlled ovarian hyperstimula- tion: a prospective, randomized, blinded clinical trial. Fertil Steril 2006;86:1428— 1431.

9. Clarke C.A., Glaser S.L. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24:49.

10. Coates A.S., Keshaviah A., Thürlimann B. et al. Five years of letro- zole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486—492.

11. Coombes R.C., Kilburn L.S., Snowdon C.F. et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;349:1110— 1117.

12. Goss P.E., Ingle J.N., Martino S. et al. Randomized trial of letrozole fol- lowing tamoxifen as extended adjuvant therapy in receptor-positive breast can- cer: updated findings from NCIC CTG MA.17. JNCI Cancer Spectrum 2005;97:1262—1271.

13. Howell A., Cuzick J., Baum M. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60—62.

14. Jakesz R., Jonat W., Gnant M. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adju- vant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455—462.

15. Winer E.P., Hudis C., Burstein H.J. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619—629.

Для цитирования:

Семиглазов В.Ф., Семиглазов В.В. СТАНДАРТЫ АДЪЮВАНТНОЙ ЭНДОКРИНОТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (по материалам 10-й Международной конференции в Сан-Галлене, Швейцария, 2007). Опухоли женской репродуктивной системы. 2008;(1):5-11.

Просмотров: 175

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)